HPS Pharmacies wish to advise that both suppliers are experiencing a supply interruption for capecitabine 500mg tablets as follows:
Xelabine
Capecitabine 500mg
ARTG 213045
Capecitabine Sandoz
Capecitabine 500mg
ARTG 201800
This supply interruption is expected to be resolved by the end of July 2025.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is registered in the US and all labelling is in English.
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
This notice only applies to the 500mg presentation. Capecitabine 150mg tablets are currently available.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download pdf
HPS Pharmacies wish to advise that Pharmaco Australia is experiencing a supply interruption for Zyprexa® IM as follows:
Zyprexa IM® Vial
Olanzapine 10mg
ARTG 76867
This supply interruption is expected to be resolved by the end of July 2025.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is registered in the USA and all labelling is in English.
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pharmaco on 1800 201 564or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that all suppliers are experiencing a supply interruption for prazosin 1mg and 2mg tablets, as follows:
| Product |
ARTG |
Estimated return date |
| APO-Prazosin 1 mg |
73858 |
End-August 2025 |
| APO-Prazosin 2 mg |
73862 |
End-August 2025 |
| Minipress 1 mg |
10756 |
End-January 2026 |
| Minipress 2 mg |
10757 |
End-January 2026 |
Minipress® 5mg tablets are currently available.
The Therapeutic Goods Administration (TGA) has authorised the supply of a Section 19A alternative for the 1mg and 2mg tablets. These products are registered in the USA and all labelling is in English. Both of the S19A alternatives are presented in capsule form (the Australian registered products are tablets).
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Fresenius Kabi has placed restrictions on the ordering of their paracetamol vials, as follows:
Paracetamol Kabi 1g/100mL Vials
Paracetamol 1g/100mL
ARTG 203624
Fresenius Kabi has advised that stock of Paracetamol Kabi vials is adequate to meet usual clinical demands. However, due to recent shipping delays, temporary ordering restrictions have been implemented to ensure equitable supply. These restrictions are expected to remain in place until 31st August 2025.
Note: This notice applies to Paracetamol Kabi vials only. There are currently no supply issues with Paracetamol Kabi bags or other brands of paracetamol for injection.
Retain this notice in a prominent position, including in other related business units until ordering restrictions cease. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wishes to advise that Pfizer is discontinuing their sodium chloride 100 mL vials as follows:
Pfizer Sodium Chloride 0.9% IV infusion
Sodium Chloride 900mg/100mL
ARTG 49280
Pfizer estimates that wholesale stock will be exhausted by September 2025. Alternative brands of 0.9% sodium chloride 100 mL vials are available.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Novo Nordisk has released a new presentation of Ozempic®, as follows:
Ozempic® 0.25/0.5mg Pen
Semaglutide 0.68 mg/mL, 3 mL
ARTG 446290
This new product replaces the Ozempic® 0.25/0.5mg 1.5 mL pen (Semaglutide 1.34mg/mL, ARTG 308324). The 1.5 mL pen will be discontinued in December 2025.
The new 3 mL Ozempic® 0.25 mg/0.5 mg pen and the older 1.5 mL Ozempic® 0.25 mg/0.5 mg pen are considered interchangeable from a bioequivalence perspective. They each deliver the same dose of active ingredient, contain the same number of doses, and have the same administration instructions. However, they are currently not ‘a-flagged’ on the Pharmaceutical Benefits Scheme (PBS).
Please click here for further information around prescribing and supplying Ozempic® on the PBS.
While Novo Nordisk continues to increase manufacturing capacity, all Ozempic® products are expected to have limited availability throughout 2025. Internationally registered alternatives have been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please be aware that additional delivery lead times may apply to Section S19A products.
For more information on availability, please go to the Ozempic (semaglutide) shortage page on the TGA website.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wishes to advise that Novo Nordisk is discontinuing Saxenda® as follows:
Saxenda®
Liraglutide (rys) 6mg/mL
ARTG 225804
Saxenda® will be discontinued on 19th December 2025. Patients currently receiving Saxenda® should discuss alternative treatment options with their prescriber.
Other injectable medications indicated for weight management include:
- Semaglutide (Wegovy®) – an alternative glucagon-like peptide-1 (GLP-1) analogue; and
- Tirzepatide (Mounjaro®) – a dual agonist at GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wishes to advise that Janssen-Cilag has discontinued all strengths of Durogesic® patches as follows:
Durogesic® Patch
Fentanyl 12 mcg/h
ARTG 116828
Durogesic® Patch
Fentanyl 25 mcg/h
ARTG 112368
Durogesic® Patch
Fentanyl 50 mcg/h
ARTG 112369
Durogesic® Patch
Fentanyl 75 mcg/h
ARTG 112370
Durogesic® Patch
Fentanyl 100 mcg/h
ARTG 112371
The discontinuation is due to manufacturing issues. Alternative brands of fentanyl patches remain available.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Janssen-Cilag on 1800 226 334 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Pfizer is anticipating a supply interruption for Bicillin® L-A as follows:
Bicillin L-A
Benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL
ARTG 147169
This supply interruption is expected to occur between 30 May 2025 and 29 August 2025.
The Therapeutic Goods Administration (TGA) has authorised the supply of an internationally registered alternative under Section 19A of the Therapeutic Goods Act 1989. This product is also listed on the Pharmaceutical Benefits Scheme (PBS). There is a lead time of 10-15 business days to access this stock.
The S19A alternative requires reconstitution prior to administration, and its final volume is approximately double that of the Australian version. This should be considered when deciding on the clinical appropriateness of this alternative. Reconstitution may be undertaken with 0.5% injectable lidocaine solution (not supplied) to reduce pain at the injection site. Other key differences between the products are shown in the table below.
| |
Bicillin® L-A |
Extencilline®
(S19A alternative) |
| Expression of active ingredient |
Benzathine benzylpenicillin
tetrahydrate |
Benzathine benzylpenicillin |
| Appearance |
White fluid suspension
Pre-filled syringe |
Vial of powder + ampoule of solvent for suspension |
| Volume required for 1.2 million IU dose |
2.3 mL |
4 mL diluent + powder = 5 mL (approx.) |
| Preparation |
Pre-filled single use syringe |
Reconstitute immediately before use |
| Labelling |
English |
French |
| Storage conditions |
2-8°C
(storage at 30°C allowed for single period of 2 months) |
Below 25°C |
For further information, including important safety considerations, please refer to the fact sheet produced by the Australian Commission on Safety and Quality in Health Care.
Please note: the lower strength of Bicillin L-A (600,000 Units/1.7mL) continues to experience a long-term supply interruption. Normal supplies of this product are not expected to return until end-September 2025.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wishes to advise that Aspen Pharmacare Australia is discontinuing Naropin® with Fentanyl injection bags as follows:
Naropin® 0.2% with Fentanyl 200 (100mL)
Ropivacaine hydrochloride 2mg/mL + fentanyl 2 microgram/mL
ARTG 72874
Naropin® 0.2% with Fentanyl 400 (100mL)
Ropivacaine hydrochloride 2 mg/mL + fentanyl 4 microgram/mL
ARTG 72876
Naropin® 0.2% with Fentanyl 400 (200mL)
Ropivacaine hydrochloride 2 mg/mL + fentanyl 2 microgram/mL
ARTG 72873
Naropin® 0.2% with Fentanyl 800 (200mL)
Ropivacaine hydrochloride 2 mg/mL + fentanyl 4 microgram/mL
ARTG 72875
There will be a reduction in supply until warehouse supplies are exhausted.
There are no alternatives available in the market. However, individual presentations of each active ingredient are available. It is recommended that relevant hospital protocols are reviewed and updated, as required.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Aspen Pharmacare on 1300 659 646 or your pharmacist at HPS Pharmacies.
Download PDF
